Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
On-chain investigator ZachXBT has alleged that presale funds tied to BlockDAG Network and ZKP were pooled together and partially redirected into influencer promotions and gambling-related marketing activity.
IperionX (ASX:IPX) commissions an advanced 300-tonne SACMI press in Virginia, tripling its US titanium powder metallurgy manufacturing capacity.
Coinbase has launched the USDF stablecoin with Flipcash as the crypto exchange expands its white-label infrastructure business for companies issuing branded digital currencies.
Securitize (NASDAQ:CEPT) reported its financial results for the first quarter ended March 31, 2026, delivering the highest quarterly revenue in the company’s history as institutional adoption of blockchain-based real-world asset (RWA) tokenization accelerated.
Immunovant (NASDAQ:IMVT) announced its corporate updates and financial results for the fourth quarter and full fiscal year ended March 31, 2026, confirming the formal termination of its first-generation autoantibody program following dual late-stage clinical trial failures.
Analog Devices (NASDAQ: ADI) reported record financial results for its fiscal second quarter of 2026 ended May 2, 2026, delivering substantial top- and bottom-line expansion.
Bitcoin remained under pressure during the midweek session as the wider crypto market struggled to recover from sharp losses across major assets.
Hasbro (NASDAQ:HAS) reported its financial results for the first quarter of 2026, delivering substantial top- and bottom-line expansion anchored by robust demand for its trading card franchises and mobile gaming partnerships.
RLX Technology (NYSE:RLX), a leading global branded electronic vapor company, announced its unaudited financial results for the first quarter of 2026, delivering substantial top- and bottom-line growth fueled by policy shifts and a strategic overseas footprint.
ImmunityBio (NASDAQ:IBRX) said the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for review, aiming to expand the approved use of its immunotherapy drug Anktiva to treat a wider patient base with non-muscle invasive bladder cancer (NMIBC).
